DexCom, Inc. $DXCM Shares Sold by HB Wealth Management LLC

HB Wealth Management LLC decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 79.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,958 shares of the medical device company’s stock after selling 19,136 shares during the quarter. HB Wealth Management LLC’s holdings in DexCom were worth $329,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in DXCM. Brighton Jones LLC boosted its position in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after purchasing an additional 11,946 shares in the last quarter. Integrated Wealth Concepts LLC boosted its position in shares of DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after purchasing an additional 196 shares in the last quarter. Empowered Funds LLC boosted its position in shares of DexCom by 5.4% in the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after purchasing an additional 436 shares in the last quarter. Focus Partners Wealth boosted its position in shares of DexCom by 13.2% in the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock worth $493,000 after purchasing an additional 841 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its position in shares of DexCom by 1.4% in the 2nd quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock worth $1,681,000 after purchasing an additional 258 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on DXCM shares. Canaccord Genuity Group set a $95.00 price objective on DexCom and gave the stock a “buy” rating in a research report on Friday, February 13th. Morgan Stanley reaffirmed an “overweight” rating on shares of DexCom in a research report on Monday, January 12th. Weiss Ratings raised DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, March 4th. Barclays reaffirmed an “underweight” rating and set a $72.00 price target (up from $71.00) on shares of DexCom in a research report on Friday, February 13th. Finally, Citigroup lifted their price target on DexCom from $77.00 to $84.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $86.50.

More DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q1 results beat expectations — EPS $0.56 vs. $0.47 consensus and revenue $1.19B vs. ~$1.17B consensus; revenue grew ~15% year‑over‑year, supporting the beat. Read More.
• Positive Sentiment: Underlying profitability and returns remain strong (reported net margin ~17.9% and ROE ~32%), reinforcing the business quality of its continuous glucose monitor (CGM) franchise. Read More.
• Neutral Sentiment: Management reaffirmed full‑year revenue guidance at roughly $5.2–5.3B (company cited a FY revenue target near $5.21B), a range that is roughly in line with consensus but left little upside. Read More.
• Neutral Sentiment: Company posted its press release, slide deck and conference‑call materials for investors to review — useful for digging into regional demand, reimbursement trends, and product cadence. Read More.
• Negative Sentiment: Market reaction was negative after hours: several outlets report shares dropped on concerns that the revenue guidance and lack of clearer upside for FY26 were disappointing relative to the beat. That suggests investors were looking for stronger forward acceleration or additional margin/cost leverage. Read More.
• Negative Sentiment: Coverage notes the stock “dipped after hours” despite beats — a reminder that beats alone may not drive gains unless guidance or cadence implies future upside above consensus. Read More.

DexCom Stock Performance

Shares of DXCM opened at $59.55 on Friday. The stock has a 50-day moving average of $65.87 and a two-hundred day moving average of $66.40. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88. The stock has a market cap of $22.98 billion, a P/E ratio of 28.36, a P/E/G ratio of 1.12 and a beta of 1.55.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The firm’s revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.32 EPS. As a group, research analysts predict that DexCom, Inc. will post 2.49 EPS for the current year.

Insider Activity

In other news, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total value of $107,168.00. Following the completion of the transaction, the executive vice president owned 111,204 shares of the company’s stock, valued at $7,010,300.16. The trade was a 1.51% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.32% of the stock is currently owned by company insiders.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.